Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism

Nutt, John G.; Gunzler, Steven A.; Kirchhoff, Trish; Hogarth, Penelope; Weaver, Jerry L.; Krams, Michael; Jamerson, Brenda; Menniti, Frank S.; Landen, Jaren W.

doi:10.1002/mds.22169

Cited by 135Parkinson's Disease Mechanisms and TreatmentsNeurological disorders and treatmentsNuclear Receptors and Signaling

Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism

Open access

Nutt, John G., Gunzler, Steven A., Kirchhoff, Trish, Hogarth, Penelope, Weaver, Jerry L., Krams, Michael, Jamerson, Brenda, Menniti, Frank S. +1 more·2008·Movement Disorders

DOI 10.1002/mds.22169PMC PMC3390310

Open this paper in CoChat — free account

Abstract

Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double‐blind, placebo‐controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP‐101,606, on the response to 2‐hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP‐101,606 reduced the maximum severity of levodopa‐induced dyskinesia ∼30% but neither dose improved Parkinsonism. CP‐101,606 was associated with a dose‐related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects. © 2008 Movement Disorder Society

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/mds.22169

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Broadly, these agents demonstrated no significant antidepressant efficacy and an adverse events profile that led to early terminations of some clinical trials in MDD, TRD, and Parkinson's disease.
“Broadly, these agents demonstrated no significant antidepressant efficacy and an adverse events profile that led to the early terminations of some clinical trials in indications such as MDD, TRD, and Parkinson's disease [169,170]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [169]
The Results (Adverse Events; page unavailable) report abnormal thinking, depersonalization, and amnesia in patients with Parkinson’s disease receiving CP-101,606. The paper does not report antidepressant efficacy in MDD or TRD, or say that adverse events led to early termination of a trial. (LLM, conf=0.84)
Experimental — accuracy not yet measured
NR2B-specific subunit antagonists such as traxoprodil, MK-0657, and eliprodil were developed but suffered similar failures.
“NR2B-specific subunit antagonists such as traxoprodil (CP-101,606), MK-0657 (CERC-301), and eliprodil (EVT-101) were developed but suffered similar failures.”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [169]
The Introduction identifies CP-101,606 as an NR2B-selective antagonist, and the References identify traxoprodil by name. The Discussion’s Conclusion says motor and cognitive effects may limit the class’s usefulness, but it does not call CP-101,606 a failure; it also suggests a lower dose might offer an acceptable balance of benefit and adverse effects. The paper does not address MK-0657 or eliprodil. (LLM, conf=0.85)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481 · see citing works
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822 · see citing works
Glutamate as a neurotransmitter in the brain: review of physiology and pathology
Meldrum, B. S. (2000) · The Journal of Nutrition · doi:10.1093/jn/130.4.1007s · Cited by 1,667 · see citing works
The “On–Off” Phenomenon in Parkinson’s Disease
Nutt, J. G., Woodward, W. R., Hammerstad, J. P., Carter, J. H., & Anderson, J. L. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402233100802 · Cited by 561 · see citing works
Self-citation
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
Metman, L. V., Dotto, P. D., van den Munckhof, P., Fang, J. Y., Mouradian, M. M., & Chase, T. N. (1998) · Neurology · doi:10.1212/wnl.50.5.1323 · Cited by 515 · see citing works
The N-methyl-d-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications
Loftis, J. M., & Janowsky, A. J. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00302-9 · Cited by 362 · see citing works
NMDA antagonists potentiate antiparkinsonian actions of L ‐dopa in monoamine‐depleted rats
Klockgether, T., & Turski, L. (1990) · Annals of Neurology · doi:10.1002/ana.410280411 · Cited by 284 · see citing works
Alterations in Subunit Expression, Composition, and Phosphorylation of Striatal N-Methyl-d-Aspartate Glutamate Receptors in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease
Dunah, A. W., Wang, Y., Yasuda, R. P., Kameyama, K., Huganir, R. L., Wolfe, B. B., & Standaert, D. G. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23206-5 · Cited by 263 · see citing works
NMDA receptor regulation of memory and behavior in humans
Newcomer, J. W., & Krystal, J. (2001) · Hippocampus · doi:10.1002/hipo.1069 · Cited by 258 · see citing works
Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease
Calon, F., Rajput, A. H., Hornykiewicz, O., Bédard, P. J., & Paolo, T. D. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.07.003 · Cited by 221 · see citing works
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
Hallett, P. J., Dunah, A. W., Ravenscroft, P., Zhou, S., Bezard, E., Crossman, A. R., Brotchie, J. M., & Standaert, D. G. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.11.008 · Cited by 192 · see citing works
(1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: A Potent New Neuroprotectant Which Blocks N-Methyl-D-Aspartate Responses
Chenard, B. L., Bordner, J., Butler, T. W., Chambers, L. K., Collins, M. A., Costa, D. L. D., Ducat, M. F., Dumont, M. L., & Fox, C. B. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00016a017 · Cited by 180 · see citing works
Differing Effects of N-methyl-d-aspartate Receptor Subtype Selective Antagonists on Dyskinesias in Levodopa-Treated 1-Methyl-4-phenyl-tetrahydropyridine Monkeys
Blanchet, P. J., Konitsiotis, S., Whittemore, E. R., Zhou, Z., Woodward, R. M., & Chase, T. N. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35003-7 · Cited by 158 · see citing works
Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease
Greenamyre, J. T., Eller, R. V., Zhang, Z., Ovadia, A., Kurlan, R., & Gash, D. M. (1994) · Annals of Neurology · doi:10.1002/ana.410350605 · Cited by 152 · see citing works
Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys
Tahar, A. H., Grégoire, L., Dare, A., Bélanger, N., Meltzer, L. T., & Bédard, P. J. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.10.007 · Cited by 141 · see citing works
The Effect of the Selective NMDA Receptor Antagonist Traxoprodil in the Treatment of Traumatic Brain Injury
Yurkewicz, L., Weaver, J., Bullock, M., & Marshall, L. (2005) · Journal of Neurotrauma · doi:10.1089/neu.2005.22.1428 · Cited by 138 · see citing works
Self-citation
Antiparkinsonian Actions of CP-101,606, an Antagonist of NR2B Subunit-Containing N-Methyl-d-Aspartate Receptors
Steece‐Collier, K., Chambers, L. K., Jaw‐Tsai, S., Menniti, F. S., & Greenamyre, J. T. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7374 · Cited by 138 · see citing works
Self-citation
Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease
Nash, J. E., Fox, S. H., Henry, B., Hill, M. P., Peggs, D., McGuire, S., Maneuf, Y. P., Hille, C. J., Brotchie, J. M., & Crossman, A. R. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7444 · Cited by 127 · see citing works
A Double‐Blind, Placebo‐Controlled Study of the Safety, Tolerability and Pharmacokinetics of CP‐101,606 in Patients with a Mild or Moderate Traumatic Brain Injury
Merchant, R. E., Bullock, M. R., Carmack, C. A., SHAH, A. K., Wilner, K. D., Ko, G. N., & Williams, S. A. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07979.x · Cited by 102 · see citing works
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease
Löschmann, P. A., de Groote, C., Smith, L. A., Wüllner, U., Fischer, G., Kemp, J. A., Jenner, P. G., & Klockgether, T. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.018 · Cited by 101 · see citing works
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease
Nash, J. E., Ravenscroft, P., McGuire, S., Crossman, A. R., Menniti, F. S., & Brotchie, J. M. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.05.004 · Cited by 94 · see citing works
Self-citation
NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats
Wessell, R., Ahmed, S. M., Menniti, F. S., Dunbar, G. L., Chase, T. N., & Oh, J. D. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.03.011 · Cited by 84 · see citing works
Self-citation
Antiparkinsonian Actions of Blockade of NR2B-Containing NMDA Receptors in the Reserpine-Treated Rat
Nash, J. E., Hill, M. P., & Brotchie, J. M. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.6963 · Cited by 80 · see citing works
Striatal glutamatergic mechanisms and extrapyramidal movement disorders
Chase, T. N., Bibbiani, F., & Oh, J. D. (2003) · Neurotoxicity Research · doi:10.1007/bf03033378 · Cited by 77 · see citing works
An Open‐Label Study of CP‐101,606 in Subjects with a Severe Traumatic Head Injury or Spontaneous Intracerebral Hemorrhage
Bullock, M. R., Merchant, R. E., Carmack, C. A., DOPPENBERG, E. M. R., SHAH, A. K., Wilner, K. D., Ko, G. N., & Williams, S. A. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07980.x · Cited by 68 · see citing works
A double-blind study of the efficacy of apomorphine and its assessment in ‘off’-periods in Parkinson's disease
van Laar, T., Jansen, E. N. H., Essink, A. W. G., Neef, C., Oosterloo, S. J., & Roos, R. A. C. (1993) · Clinical Neurology and Neurosurgery · doi:10.1016/0303-8467(93)90128-4 · Cited by 59 · see citing works
Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP‐treated common marmosets
Hurley, M. J., Jackson, M. J., Smith, L. A., Rose, S., & Jenner, P. G. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04169.x · Cited by 45 · see citing works
Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease
Metman, L. V., van den Munckhof, P., Klaassen, A. A. G., Blanchet, P. J., Mouradian, M. M., & Chase, T. N. (1997) · Neurology · doi:10.1212/wnl.49.3.711 · Cited by 44 · see citing works
“On–Off” Phenomenon in Parkinson’s Disease
Breitner, J. C., & Folstein, M. F. (1984) · New England Journal of Medicine · doi:10.1056/nejm198407193110316 · Cited by 30 · see citing works
CP-101606 Pfizer Inc.
Chazot, P. L. (2000) · PubMed · Cited by 23 · see citing works
Movement Characteristics in Parkinsonʼs Disease
van Hilten, J. J., Wagemans, E. A. H., Ghafoerkhan, S. F., & van Laar, T. (1997) · Clinical Neuropharmacology · doi:10.1097/00002826-199710000-00004 · Cited by 13 · see citing works

Flagged first, then by citations

1 of the 32 references couldn’t be matched to a known paper.

Sorted by citations

Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · see citing works
Self-citation
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686 · see citing works
Self-citation
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P., Feyder, M. T., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 470 · see citing works
Priorities in Parkinson's disease research
Meissner, W. G., Frasier, M. A., Gasser, T., Goetz, C. G., Lozano, A. M., Piccini, P. P., Obeso, J. A., Rascol, O., Schapira, A. H. V., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 439 · see citing works
Allosteric modulators of NR2B‐containing NMDA receptors: molecular mechanisms and therapeutic potential
Mony, L., Kew, J. N. C., Gunthorpe, M. J., & Paoletti, P. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00304.x · Cited by 404 · see citing works
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
Calabresi, P., Filippo, M. D., Ghiglieri, V., Tambasco, N., & Picconi, B. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70218-0 · Cited by 390 · see citing works
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324 · see citing works
Glutamate Receptors as Therapeutic Targets for Parkinsons Disease
Johnson, K. A., Conn, P. J., & Niswender, C. M. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824606 · Cited by 251 · see citing works
Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems
Brichta, L., Greengard, P., & Flajolet, M. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.06.003 · Cited by 224 · see citing works
NMDA Receptors in the Central Nervous System
Hansen, K. B., Yi, F., Perszyk, R. E., Menniti, F. S., & Traynelis, S. F. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7321-7_1 · Cited by 206 · see citing works
Self-citation
A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease
Ambrosi, G., Cerri, S., & Blandini, F. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-013-1149-z · Cited by 195 · see citing works
Pharmacological Modulation of Glutamate Transmission in a Rat Model of l-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling
Ottosson, D. R., Recchia, A., Mela, F., Dekundy, A., Danysz, W., & Cenci, M. A. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.150425 · Cited by 172 · see citing works
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
Sgambato, V., & Cenci, M. A. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.10.005 · Cited by 169 · see citing works
Target- and Mechanism-Based Therapeutics for Neurodegenerative Diseases: Strength in Numbers
Trippier, P. C., Labby, K. J., Hawker, D. D., Mataka, J., & Silverman, R. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3015926 · Cited by 141 · see citing works
Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease
Johnston, T. H., Fox, S. H., McIldowie, M. J., Piggott, M., & Brotchie, J. M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166629 · Cited by 137 · see citing works
Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
Kalia, L., Brotchie, J., & Fox, S. H. (2013) · Movement Disorders · doi:10.1002/mds.25273 · Cited by 116 · see citing works
Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry
Hanson, J. E., Yuan, H., Perszyk, R. E., Banke, T. G., Xing, H., Tsai, M., Menniti, F. S., & Traynelis, S. F. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01614-3 · Cited by 116 · see citing works
Self-citation
Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias
Rascol, O., Fox, S. H., Gasparini, F., Kenney, C., Paolo, T. D., & Gomez‐Mancilla, B. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.05.003 · Cited by 115 · see citing works
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
Vijayakumar, D., & Jankovic, J. J. (2016) · Drugs · doi:10.1007/s40265-016-0566-3 · Cited by 112 · see citing works
Animal Models of Parkinson's Disease: A Gateway to Therapeutics?
Le, W., Sayana, P., & Jankovic, J. J. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0234-1 · Cited by 106 · see citing works
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108 · see citing works
Ion Channels as Drug Targets in Central Nervous System Disorders
Waszkielewicz, A. M., Gunia‐Krzyżak, A., Szkaradek, N., Słoczyńska, K., Krupinska, S., & Marona, H. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320100005 · Cited by 100 · see citing works
Allosteric Modulators for the Treatment of Schizophrenia: Targeting Glutamatergic Networks
Menniti, F. S., Lindsley, C. W., Conn, P. J., Pandit, J., Zagouras, P., & Volkmann, R. A. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313010005 · Cited by 87 · see citing works
Self-citation
Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model
Chotibut, T., Davis, R. W., Arnold, J. C., Frenchek, Z., Gurwara, S., Bondada, V., Geddes, J. W., & Salvatore, M. F. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8598-0 · Cited by 86 · see citing works
A comprehensive description of GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists
Liu, W., Jiang, X., Zu, Y., Yue, Y., Liu, Y., Sun, X., Xu, Z., Ding, H., & Zhao, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112447 · Cited by 85 · see citing works
NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients
Mellone, M., Stanic, J., Hernández, L. F., Iglesias, E., Zianni, E., Longhi, A., Prigent, A., Picconi, B., Calabresi, P., Hirsch, É. C., et al. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00245 · Cited by 84 · see citing works
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation
Iravani, M. M., & Jenner, P. G. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0698-2 · Cited by 80 · see citing works
Levodopa-Induced Dyskinesias in Parkinson’s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions
di Biase, L., Pecoraro, P. M., Carbone, S. P., Caminiti, M. L., & Lazzaro, V. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134427 · Cited by 86 · see citing works
Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease
Duty, S. (2012) · CNS Drugs · doi:10.1007/s40263-012-0016-z · Cited by 74 · see citing works
Context-Dependent GluN2B-Selective Inhibitors of NMDA Receptor Function are Neuroprotective with Minimal Side Effects
Yuan, H.-J., Myers, S. J., Wells, G., Nicholson, K., Swanger, S., Lyuboslavsky, P., Tahirovic, Y., Menaldino, D., Ganesh, T., Wilson, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.008 · Cited by 72 · see citing works
Altered tryptophan metabolism in Parkinson's disease: A possible novel therapeutic approach
Szabó, N., Kincses, Z. T., Toldi, J., & Vécsei, L. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.07.021 · Cited by 68 · see citing works
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys
Morin, N., Morissette, M., Grégoire, L., Gomez‐Mancilla, B., Gasparini, F., & Paolo, T. D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.028 · Cited by 65 · see citing works
Metabotropic Glutamate Receptors for Parkinson's Disease Therapy
Gasparini, F., Paolo, T. D., & Gomez‐Mancilla, B. (2013) · Parkinson s Disease · doi:10.1155/2013/196028 · Cited by 63 · see citing works
New pharmacological avenues for the treatment of l -DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors
Blandini, F., & Armentero, M. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.651457 · Cited by 61 · see citing works
From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease
Jenner, P. G. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70829-6 · Cited by 60 · see citing works
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease
Cenci, M. A., Skovgård, K., & Odin, P. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109027 · Cited by 58 · see citing works
l-Dopa-Induced Dyskinesia—Clinical Presentation, Genetics, and Treatment
Kukkle, P. L., Fox, S. H., & Meissner, W. G. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00002-x · Cited by 56 · see citing works
Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies
Sharma, S., Singh, S., Sharma, V., Singh, V. P., & Deshmukh, R. R. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.01.029 · Cited by 56 · see citing works
Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
Bandopadhyay, R., Mishra, N., Rana, R., Kaur, G., Ghoneim, M. M., Alshehri, S., Mustafa, G., Ahmad, J., Alhakamy, N. A., & Mishra, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.805388 · Cited by 55 · see citing works
Ceftriaxone reduces <scp>L</scp> ‐dopa–induced dyskinesia severity in 6‐hydroxydopamine parkinson's disease model
Chotibut, T., Meadows, S., Kasanga, E. A., McInnis, T., Cantu, M. A., Bishop, C., & Salvatore, M. F. (2017) · Movement Disorders · doi:10.1002/mds.27077 · Cited by 56 · see citing works
Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
Schaeffer, E., Pilotto, A., & Berg, D. (2014) · CNS Drugs · doi:10.1007/s40263-014-0205-z · Cited by 54 · see citing works
N -Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present)
Ahmed, H., Haider, A., & Ametamey, S. M. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1811234 · Cited by 54 · see citing works
GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases
Ladagu, A., Olopade, F., Adejare, A., & Olopade, J. (2023) · Pharmaceuticals · doi:10.3390/ph16111535 · Cited by 51 · see citing works
Dyskinesia and the antiparkinsonian response always temporally coincide
Nutt, J. G., Chung, K. A., & Holford, N. H. G. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d90050 · Cited by 52 · see citing works
Self-citation
Dock GEFs and their therapeutic potential: Neuroprotection and axon regeneration
Namekata, K., Kimura, A., Kawamura, K., Harada, C., & Harada, T. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.06.005 · Cited by 57 · see citing works
Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia
Errico, F., Bonito-Oliva, A., Bagetta, V., Vitucci, D., Romano, R., Zianni, E., Napolitano, F., Marinucci, S., Luca, M. D., Calabresi, P., et al. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.09.013 · Cited by 45 · see citing works
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
Konitsiotis, S., & Bargiotas, P. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36693 · Cited by 45 · see citing works
L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.
Paul, R., & Borah, A. (2016) · Biochimica et Biophysica Acta · doi:10.1016/j.bbagen.2016.06.018 · Cited by 44 · see citing works
Therapeutic potential of targeting glutamate receptors in Parkinson’s disease
Finlay, C. J., & Duty, S. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1176-4 · Cited by 41 · see citing works
Targeting glutamatergic synapses in Parkinson's disease
Gardoni, F., & Luca, M. D. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.10.011 · Cited by 40 · see citing works
Treatment of Parkinson's Disease: What's in the Non-dopaminergic Pipeline?
Hung, A. Y., & Schwarzschild, M. A. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0239-9 · Cited by 38 · see citing works
Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update
Leta, V., Jenner, P. G., Chaudhuri, К. R., & Antonini, A. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1681966 · Cited by 39 · see citing works
Glutamate in Parkinson's disease: Role of antiglutamatergic drugs
Carrillo-Mora, P. U., Silva‐Adaya, D., & Villaseñor-Aguayoa, K. (2013) · Basal Ganglia · doi:10.1016/j.baga.2013.09.001 · Cited by 37 · see citing works
Mavoglurant as a treatment for Parkinson’s disease
Petrov, D., Pedrós, I., de Lemos, M. L., Pallàs, M., Canudas, A. M., Lazarowski, A., Beas‐Zárate, C., Auladell, C., Folch, J., & Camins, A. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.931370 · Cited by 36 · see citing works
Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection
Pirooznia, S. K., Rosenthal, L. S., Dawson, V. L., & Dawson, T. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000189 · Cited by 36 · see citing works
Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease
Brod, L. S., Aldred, J. L., & Nutt, J. G. (2012) · Movement Disorders · doi:10.1002/mds.24998 · Cited by 35 · see citing works
Self-citation
Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey
Veyres, N., Hamadjida, A., & Huot, P. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.247171 · Cited by 34 · see citing works
Modulation of NMDA receptor at the synapse: Promising therapeutic interventions in disorders of the nervous system
Mellone, M., & Gardoni, F. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.04.054 · Cited by 33 · see citing works
Pivotal Role of Fyn Kinase in Parkinson’s Disease and Levodopa-Induced Dyskinesia: a Novel Therapeutic Target?
Angelopoulou, E., Paudel, Y. N., Julian, T. H., Shaikh, M. F., & Piperi, C. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02201-z · Cited by 33 · see citing works
l-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective
Buck, K., & Ferger, B. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.08.014 · Cited by 32 · see citing works
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
Bello, F. D., Giannella, M., Giorgioni, G., Piergentili, A., & Quaglia, W. (2019) · Biomolecules · doi:10.3390/biom9040142 · Cited by 32 · see citing works
Identification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor
Haider, A., Iten, I., Ahmed, H., Herde, A. M., Gruber, S., Krämer, S. D., Keller, C., Schibli, R., Wünsch, B., Mu, L., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.212134 · Cited by 30 · see citing works
Preclinical Evaluation of Benzazepine-Based PET Radioligands (R)- and (S)-11C-Me-NB1 Reveals Distinct Enantiomeric Binding Patterns and a Tightrope Walk Between GluN2B- and σ1-Receptor–Targeted PET Imaging
Haider, A., Herde, A. M., Krämer, S. D., Varisco, J., Keller, C., Frauenknecht, K. B. M., Auberson, Y. P., Temme, L., Robaa, D., Sippl, W., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.221051 · Cited by 30 · see citing works
NYX‐458 Improves Cognitive Performance in a Primate Parkinson's Disease Model
Barth, A., Schneider, J. S., Johnston, T. H., Hill, M. P., Brotchie, J. M., Moskal, J. R., & Cearley, C. N. (2020) · Movement Disorders · doi:10.1002/mds.27962 · Cited by 30 · see citing works
Differential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant Efficacy
Nagy, D., Stoiljković, M., Menniti, F. S., & Hajós, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.298 · Cited by 29 · see citing works
Self-citation
Glutamatergic mechanisms in l-DOPA-induced dyskinesia and therapeutic implications
Mellone, M., & Gardoni, F. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1846-8 · Cited by 29 · see citing works
Structure–Affinity Relationships of 2,3,4,5-Tetrahydro-1H-3-benzazepine and 6,7,8,9-Tetrahydro-5H-benzo[7]annulen-7-amine Analogues and the Discovery of a Radiofluorinated 2,3,4,5-Tetrahydro-1H-3-benzazepine Congener for Imaging GluN2B Subunit-Containing N-Methyl- d -aspartate Receptors
Ahmed, H., Haider, A., Varisco, J., Stanković, M., Wallimann, R. H., Gruber, S., Iten, I., Häne, S., Herde, A. M., Keller, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00812 · Cited by 27 · see citing works
Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease
Cenci, M. A. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140006 · Cited by 27 · see citing works
The MPTP-lesioned marmoset model of Parkinson’s disease: proposed efficacy thresholds that may potentially predict successful clinical trial results
Beaudry, F., & Huot, P. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02247-2 · Cited by 25 · see citing works
Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains
Weed, M. R., Bookbinder, M., Polino, J. L., Keavy, D., Cardinal, R. N., Simmermacher, J., Cometa, F.-N. L., King, D., Thangathirupathy, S., Macor, J. E., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.184 · Cited by 25 · see citing works
Chronic GluN2B Antagonism Disrupts Behavior in Wild-Type Mice Without Protecting Against Synapse Loss or Memory Impairment in Alzheimer's Disease Mouse Models
Hanson, J. E., Meilandt, W. J., Gogineni, A., Reynen, P. H., Herrington, J. B., Weimer, R. M., Scearce-Levie, K. A., & Zhou, Q. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.5106-13.2014 · Cited by 25 · see citing works
Unprecedented Therapeutic Potential with a Combination of A2A/NR2B Receptor Antagonists as Observed in the 6-OHDA Lesioned Rat Model of Parkinson's Disease
Michel, A., Downey, P. M., Nicolas, J.-M., & Scheller, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114086 · Cited by 24 · see citing works
A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-d-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease
Herring, W. J., Assaid, C. A., Budd, K., Vargo, R. C., Mazenko, R. S., Lines, C., Ellenbogen, A. L., & Metman, L. V. (2017) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000241 · Cited by 24 · see citing works
Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
Frouni, I., Belliveau, S., Maddaford, S. P., Nuara, S. G., Gourdon, J. C., & Huot, P. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174452 · Cited by 24 · see citing works
The Kinase Fyn As a Novel Intermediate in l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Sanz‐Blasco, S., Bordone, M., Damianich, A., Gómez, G., Bernardi, A., Isaja, L., Taravini, I. R. E., Hanger, D. P., Avale, M. E., Gershanik, O. S., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0748-3 · Cited by 24 · see citing works
PTC-174, a positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits
Yi, F., Rouzbeh, N., Hansen, K. B., Xu, Y., Fanger, C. M., Gordon, E., Paschetto, K. A., Menniti, F. S., & Volkmann, R. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107971 · Cited by 24 · see citing works
Self-citation
Research advances on L-DOPA-induced dyskinesia: from animal models to human disease
Chen, X., Wang, Y., Wu, H., Cheng, C., & Le, W. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04333-5 · Cited by 24 · see citing works
Diminution of the NMDA receptor NR2Bsubunit in cortical and subcortical areas of WAG/Rij rats
Karimzadeh, F., Soleimani, M., Mehdizadeh, M., Jafarian, M., Mohamadpour, M., Kazemi, H., Joghataei, M. T., & Gorji, A. (2013) · Synapse · doi:10.1002/syn.21687 · Cited by 23 · see citing works
A series of structurally novel heterotricyclic α‐amino‐3‐hydroxyl‐5‐methyl‐4‐isoxazole‐propionate receptor‐selective antagonists
Gill, M., Frausto, S. F., Ikoma, M., Sasaki, M., Oikawa, M., Sakai, R., & Swanson, G. T. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00784.x · Cited by 23 · see citing works
Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients
Mišković, N., Petrović, I. N., Stanković, I., & Kostić, V. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1543407 · Cited by 22 · see citing works
Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease
Tallaksen‐Greene, S. J., Janiszewska, A., Benton, K., Ruprecht, L., & Albin, R. L. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.07.015 · Cited by 21 · see citing works
Parkinson's disease: emerging pharmacotherapy
Strecker, K., & Schwarz, J. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802596906 · Cited by 21 · see citing works
The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease
Liu, Z., Yan, A., Zhao, J., Yang, S., Song, L., & Liu, Z. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113740 · Cited by 21 · see citing works
The role of glutamate receptors and their interactions with dopamine and other neurotransmitters in the development of tardive dyskinesia: preclinical and clinical results
Szota, A. M., & Scheel‐Krüger, J. (2020) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000563 · Cited by 20 · see citing works
Forelimb dyskinesia mediated by high‐frequency stimulation of the subthalamic nucleus is linked to rapid activation of the NR2B subunit ofN‐methyl‐ d ‐aspartate receptors
Quintana, A., Melon, C., Goff, L. K., Salin, P., Savasta, M., & Sgambato, V. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07290.x · Cited by 19 · see citing works
Variations in the stimulus salience of cocaine reward influences drug‐associated contextual memory
Liddie, S., & Itzhak, Y. (2014) · Addiction Biology · doi:10.1111/adb.12191 · Cited by 19 · see citing works
Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias
Cerri, S., Siani, F., & Blandini, F. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1333598 · Cited by 18 · see citing works
Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets
Michel, A., Nicolas, J.-M., Rose, S., Jackson, M., Colman, P., Briône, W., Sciberras, D. G., Muglia, P., Scheller, D., Citron, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182887 · Cited by 17 · see citing works
Dyskinesia and Parkinson’s disease: animal model, drug targets, and agents in preclinical testing
Cesaroni, V., Blandini, F., & Cerri, S. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2153036 · Cited by 16 · see citing works
Novel GluN2B-Selective NMDA Receptor Negative Allosteric Modulator Possesses Intrinsic Analgesic Properties and Enhances Analgesia of Morphine in a Rodent Tail Flick Pain Model
Harris, L. D., Regan, M. C., Myers, S. J., Nocilla, K. A., Akins, N. S., Tahirovic, Y. A., Wilson, L. J., Dingledine, R. J., Furukawa, H., Traynelis, S. F., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00779 · Cited by 16 · see citing works
Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease
Quintana, A., Sgambato, V., & Savasta, M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.06.009 · Cited by 16 · see citing works
GluN2A and GluN2B NMDA Receptor Subunits Differentially Modulate Striatal Output Pathways and Contribute to Levodopa-Induced Abnormal Involuntary Movements in Dyskinetic Rats
Mabrouk, O. S., Mela, F., Calcagno, M., Budri, M., Viaro, R., Dekundy, A., Parsons, C. G., Auberson, Y. P., & Morari, M. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400016d · Cited by 16 · see citing works
Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease
Du, J., & Chen, S. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.211555 · Cited by 15 · see citing works
Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson’s rats
Wang, X., Zhang, Z., Zhang, X.-R., Chen, S., Shao, B., & Xie, C. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.062 · Cited by 15 · see citing works
A Glutamate N-Methyl-d-Aspartate (NMDA) Receptor Subunit 2B–Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use
Myers, S. J., Ruppa, K. P., Wilson, L., Tahirovic, Y., Lyuboslavsky, P., Menaldino, D., Dentmon, Z. W., Koszalka, G. W., Zaczek, R., Dingledine, R., et al. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000370 · Cited by 14 · see citing works
Effect of the Metabotropic Glutamate Receptor Type 5 Negative Allosteric Modulator Dipraglurant on Motor and Non-Motor Symptoms of Parkinson’s Disease
Epping-Jordan, M. P., Girard, F., Bessis, A., Mutel, V., Boléa, C., Derouet, F., Bessif, A., Mingard, B., Barbier, S., Paradis, J. S., et al. (2023) · Cells · doi:10.3390/cells12071004 · Cited by 14 · see citing works
Differential effects of traxoprodil and S-ketamine on quantitative EEG and auditory event-related potentials as translational biomarkers in preclinical trials in rats and mice
Raith, H., Schuelert, N., Duveau, V., Roucard, C., Plano, A., Dorner‐Ciossek, C., & Ferger, B. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108072 · Cited by 14 · see citing works
New insights into pathogenesis of l-DOPA-induced dyskinesia
Zheng, C.-Q., & Zhang, F. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.07.006 · Cited by 14 · see citing works
Glutamate Modulation for the Treatment of Levodopa Induced Dyskinesia: A Brief Review of the Drugs Tested in the Clinic
Frouni, I., & Huot, P. (2022) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0055 · Cited by 13 · see citing works
Translational psychiatry—light at the end of the tunnel
Jones, K., Menniti, F. S., & Sivarao, D. V. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12725 · Cited by 13 · see citing works
Self-citation

Antiparkinsonian Actions of CP-101,606, an Antagonist of NR2B Subunit-Containing N-Methyl-d-Aspartate Receptors
Steece‐Collier, K., Chambers, L. K., Jaw‐Tsai, S., Menniti, F. S., & Greenamyre, J. T. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7374 · Cited by 138 · see citing works
Self-citation
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease
Nash, J. E., Ravenscroft, P., McGuire, S., Crossman, A. R., Menniti, F. S., & Brotchie, J. M. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.05.004 · Cited by 94 · see citing works
Self-citation
Levodopa‐induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys
Papa, S. M., & Chase, T. N. (1996) · Annals of Neurology · doi:10.1002/ana.410390505 · Cited by 292 · see citing works
Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys
Tahar, A. H., Grégoire, L., Dare, A., Bélanger, N., Meltzer, L. T., & Bédard, P. J. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.10.007 · Cited by 141 · see citing works
Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study
Dotto, P. D., Pavese, N., Gambaccini, G., Bernardini, S., Metman, L. V., Chase, T. N., & Bonuccelli, U. (2001) · Movement Disorders · doi:10.1002/mds.1112 · Cited by 153 · see citing works

Authors: Nutt, J. G., Gunzler, S. A., Kirchhoff, T., Hogarth, P., Weaver, J. L., Krams, M., Jamerson, B., Menniti, F. S., & Landen, J. W.
Affiliations: Oregon Health & Science University (US)
Pfizer (United States) (US)
Campbell University (US)
Corresponding author: Nutt, John G.
ORCID: Nutt, John G.
Gunzler, Steven A.
Hogarth, Penelope
Menniti, Frank S.
Venue: Movement Disorders
Publisher: Wiley
Published: 2008-10-15
Volume: 23
Issue: 13
Pages: 1860-1866
ISSN: 0885-3185 (ISSN-L)
1531-8257
DOI: 10.1002/mds.22169
PMC: PMC3390310
OpenAlex: W1982761758
Cited by: 133
References: 32
Citations by year: 2025: 2 · 2023: 7 · 2022: 5 · 2021: 9 · 2020: 11 · 2019: 6 · 2018: 7 · 2017: 7 · 2016: 5 · 2015: 10 · 2014: 13 · 2013: 19 · 2012: 6
FWCI: 5.51
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Movement Disorders (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Deutsches Krebsforschungszentrum
National Institute of Neurological Disorders and Stroke (R01NS021062)
National Center for Research Resources (UL1RR024140)
Topics: Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Neurology › Neurological disorders and treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
Keywords: CP-101,606, NR2B subunit, NMDA receptor antagonists, glutamate receptor antagonists, levodopa-induced dyskinesia, parkinsonism, Parkinson's disease, motor fluctuations, dissociation, amnesia, cognitive side effects
MeSH terms: Aged, Double-Blind Method, Humans, Levodopa, Middle Aged, Piperidines, Severity of Illness Index, Dopamine Agents, Cross-Over Studies, Excitatory Amino Acid Antagonists, Parkinsonian Disorders, Dyskinesias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks